Fluarix quadrivalent vaccine for influenza

Cost-effectiveness analysis of quadrivalent influenza vaccine versus trivalent influenza vaccine for elderly in Hong Kong

(2014) Joyce HS You et al.   BMC INFECTIOUS DISEASES

A historically-controlled Phase III study in adults to characterize the acceptability of a process change for manufacturing inactivated quadrivalent influenza vaccine

(2014) Varsha K Jain et al.   BMC INFECTIOUS DISEASES

Annual public health and economic benefits of seasonal influenza vaccination: a European estimate

(2014) Emmanuelle Preaud et al.   BMC PUBLIC HEALTH

Effectiveness of trivalent seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2012/13 end of season results

(2014) N Andrews et al.   Eurosurveillance

Intranasal formulations: promising strategy to deliver vaccines

(2014) Peggy Riese et al.   Expert Opinion on Drug Delivery

Effectiveness of Influenza Vaccine Against Life-threatening RT-PCR-confirmed Influenza Illness in US Children, 2010–2012

(2014) Jill M. Ferdinands et al.   JOURNAL OF INFECTIOUS DISEASES

Immunogenicity and Safety of Inactivated Quadrivalent and Trivalent Influenza Vaccines in Children 18–47 Months of Age

(2014) Miguel A. Rodriguez Weber et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

The Potential Cost-Effectiveness of Quadrivalent versus Trivalent Influenza Vaccine in Elderly People and Clinical Risk Groups in the UK: A Lifetime Multi-Cohort Model

(2014) Laure-Anne Van Bellinghen et al.   PLoS One

Immunogenicity, reactogenicity, and safety of inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine in healthy adults aged ≥18 years: A phase III, randomized trial

(2014) Juan Carlos Tinoco et al.   VACCINE

WHO recommendations for the viruses used in the 2013–2014 Northern Hemisphere influenza vaccine: Epidemiology, antigenic and genetic characteristics of influenza A(H1N1)pdm09, A(H3N2) and B influenza viruses collected from October 2012 to January 2013

(2014) Ian G. Barr et al.   VACCINE

Cost-effectiveness analysis of universal influenza vaccination with quadrivalent inactivated vaccine in the United States

(2014) Karen M Clements et al.   Human Vaccines & Immunotherapeutics

Immunogenicity and safety of quadrivalent versus trivalent inactivated influenza vaccine: a randomized, controlled trial in adults

(2013) Jiří Beran et al.   BMC INFECTIOUS DISEASES

Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged ≥18 years

(2013) Dorothee Kieninger et al.   BMC INFECTIOUS DISEASES

Immunogenicity and Safety of an Inactivated Quadrivalent Influenza Vaccine Candidate: A Phase III Randomized Controlled Trial in Children

(2013) Joanne M. Langley et al.   JOURNAL OF INFECTIOUS DISEASES

A Randomized Trial of Candidate Inactivated Quadrivalent Influenza Vaccine versus Trivalent Influenza Vaccines in Children Aged 3–17 Years

(2013) Joseph B. Domachowske et al.   JOURNAL OF INFECTIOUS DISEASES

Vaccine for Prevention of Mild and Moderate-to-Severe Influenza in Children

(2013) Varsha K. Jain et al.   NEW ENGLAND JOURNAL OF MEDICINE

Influenza-Associated Pediatric Deaths in the United States, 2004-2012

(2013) K. K. Wong et al.   PEDIATRICS

Cochrane re-arranged: Support for policies to vaccinate elderly people against influenza

(2013) Walter E.P. Beyer et al.   VACCINE

Preliminary Assessment of the Efficacy of a T-Cell–Based Influenza Vaccine, MVA-NP+M1, in Humans

(2012) Patrick J. Lillie et al.   CLINICAL INFECTIOUS DISEASES

The Coming Era of Quadrivalent Human Influenza Vaccines

(2012) Ian G. Barr et al.   DRUGS

Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine

(2012) Carrie Reed et al.   VACCINE

The rationale for quadrivalent influenza vaccines

(2012) Christopher S. Ambrose et al.   Human Vaccines & Immunotherapeutics

Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis

(2011) Harish Nair et al.   LANCET

DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials

(2011) Julie E Ledgerwood et al.   LANCET INFECTIOUS DISEASES

Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis

(2011) Michael T Osterholm et al.   LANCET INFECTIOUS DISEASES

Safety and immunogenicity of a recombinant M2e–flagellin influenza vaccine (STF2.4xM2e) in healthy adults

(2011) Christine B. Turley et al.   VACCINE